• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Preliminary study on immunological changes and clinical significance of decitabine treatment for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].

作者信息

Cao X H, Zhao X S, Chang Y J, Xu L P, Zhang X H, Wang Y, Liu K Y, Huang X J, Zhao X Y

机构信息

Peking University People's Hospital & Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Blood Diseases, Beijing 100044, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2020 Dec 14;41(12):1035-1040. doi: 10.3760/cma.j.issn.0253-2727.2020.12.012.

DOI:10.3760/cma.j.issn.0253-2727.2020.12.012
PMID:33445853
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7840555/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f9b/7840555/a21c905932a4/cjh-41-12-1035-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f9b/7840555/ab99e3accd54/cjh-41-12-1035-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f9b/7840555/d1f7bf643211/cjh-41-12-1035-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f9b/7840555/a21c905932a4/cjh-41-12-1035-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f9b/7840555/ab99e3accd54/cjh-41-12-1035-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f9b/7840555/d1f7bf643211/cjh-41-12-1035-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f9b/7840555/a21c905932a4/cjh-41-12-1035-g003.jpg

相似文献

1
[Preliminary study on immunological changes and clinical significance of decitabine treatment for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].[地西他滨治疗异基因造血干细胞移植后复发急性髓系白血病的免疫变化及临床意义的初步研究]
Zhonghua Xue Ye Xue Za Zhi. 2020 Dec 14;41(12):1035-1040. doi: 10.3760/cma.j.issn.0253-2727.2020.12.012.
2
Decitabine+ CAG +DLI in relapsed acute myeloid leukemia after allogeneic stem cell transplantation.地西他滨 + CAG + 供者淋巴细胞输注用于异基因造血干细胞移植后复发的急性髓系白血病
J BUON. 2016 Jan-Feb;21(1):280-1.
3
Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia.异基因造血干细胞移植后使用地西他滨进行维持治疗以预防高危急性髓系白血病复发。
Bone Marrow Transplant. 2020 Jun;55(6):1206-1208. doi: 10.1038/s41409-019-0677-z. Epub 2019 Sep 18.
4
Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).地西他滨用于异基因造血干细胞移植（allo-SCT）后复发的急性髓系白血病（AML）患者。
Ann Hematol. 2013 Apr;92(4):549-50. doi: 10.1007/s00277-012-1607-y. Epub 2012 Oct 31.
5
D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation.
Ann Hematol. 2016 Jan;95(1):157-159. doi: 10.1007/s00277-015-2505-x. Epub 2015 Sep 18.
6
[Effect of decitabine on immune regulation in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Oct;22(5):1448-52. doi: 10.7534/j.issn.1009-2137.2014.05.050.
7
Studies of decitabine with allogeneic progenitor cell transplantation.地西他滨与异基因祖细胞移植的研究。
Leukemia. 1997 Mar;11 Suppl 1:S32-4.
8
Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report.地西他滨联合 CLAG 化疗桥接 HLA 匹配同胞供体移植后急性髓系白血病复发行单倍体相合移植：1 例报告。
BMC Cancer. 2019 Mar 18;19(1):242. doi: 10.1186/s12885-019-5464-0.
9
[Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].[采用FLAG序贯白消安/环磷酰胺预处理方案进行异基因造血干细胞移植治疗难治/复发急性髓系白血病的临床结局]
Zhonghua Nei Ke Za Zhi. 2018 Aug 1;57(8):576-581. doi: 10.3760/cma.j.issn.0578-1426.2018.08.008.
10
Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.维奈托克联合地西他滨可诱导造血干细胞移植后复发的急性髓系白血病完全缓解并伴有分子学反应。
Am J Hematol. 2019 Feb;94(2):E48-E50. doi: 10.1002/ajh.25352. Epub 2018 Nov 29.

引用本文的文献

1
Impact of Decitabine Conditioning on Allo-HSCT Outcomes in AML and Intermediate-to-High-Risk MDS Patients in Remission.地西他滨预处理对处于缓解期的急性髓系白血病及中高危骨髓增生异常综合征患者异基因造血干细胞移植结局的影响
Cancer Med. 2025 Jul;14(14):e71081. doi: 10.1002/cam4.71081.
2
[Efficacy and safety of venetoclax combined with decitabine, modified HA regimen and DLI in the treatment of relapsed pediatric AML/MDS after allogeneic hematopoietic stem cell transplantation].维奈克拉联合地西他滨、改良HA方案及供者淋巴细胞输注治疗儿童异基因造血干细胞移植后复发急性髓系白血病/骨髓增生异常综合征的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2024 Sep 14;45(9):832-837. doi: 10.3760/cma.j.cn121090-20240317-00099.

本文引用的文献

1
The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China.中国异基因造血干细胞移植后白血病复发的监测、治疗和预防共识。
Cancer Lett. 2018 Dec 1;438:63-75. doi: 10.1016/j.canlet.2018.08.030. Epub 2018 Sep 11.
2
Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT.异基因造血干细胞移植后复发 AML 患者中，第一供者淋巴细胞输注可逆转 T 细胞耗竭，并与持久有效的抗白血病反应相关。
Biol Blood Marrow Transplant. 2018 Jul;24(7):1350-1359. doi: 10.1016/j.bbmt.2018.03.030. Epub 2018 Apr 9.
3
Effect of the in vivo application of granulocyte colony-stimulating factor on NK cells in bone marrow and peripheral blood.
粒细胞集落刺激因子体内应用对骨髓和外周血 NK 细胞的影响。
J Cell Mol Med. 2018 Jun;22(6):3025-3034. doi: 10.1111/jcmm.13539. Epub 2018 Mar 25.
4
Decitabine enhances targeting of AML cells by CD34 progenitor-derived NK cells in NOD/SCID/IL2Rg mice.地西他滨增强 CD34 祖细胞衍生的 NK 细胞对 NOD/SCID/IL2Rg 小鼠中 AML 细胞的靶向作用。
Blood. 2018 Jan 11;131(2):202-214. doi: 10.1182/blood-2017-06-790204. Epub 2017 Nov 14.
5
NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors.慢性淋巴细胞白血病中的自然杀伤细胞功能障碍与表达抑制性杀伤细胞免疫球蛋白样受体的成熟细胞缺失有关。
Oncoimmunology. 2017 May 19;6(7):e1330235. doi: 10.1080/2162402X.2017.1330235. eCollection 2017.
6
Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.化疗与去甲基化药物治疗异基因造血干细胞移植后复发的急性髓系白血病和骨髓增生异常综合征的对比
Biol Blood Marrow Transplant. 2016 Jul;22(7):1324-1329. doi: 10.1016/j.bbmt.2016.03.023. Epub 2016 Mar 26.
7
Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation.风险分层指导下的供者淋巴细胞输注可降低异基因造血干细胞移植后标准风险急性白血病患者的复发率。
Blood. 2012 Apr 5;119(14):3256-62. doi: 10.1182/blood-2011-09-380386. Epub 2012 Feb 14.
8
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).阿扎胞苷可增强急性髓系白血病（AML）患者异基因干细胞移植后调节性 T 细胞的扩增。
Blood. 2012 Apr 5;119(14):3361-9. doi: 10.1182/blood-2011-09-377044. Epub 2012 Jan 10.
9
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.阿扎胞苷治疗异基因造血干细胞移植后 MDS 或 AML 患者即将复发：RELAZA 试验结果。
Leukemia. 2012 Mar;26(3):381-9. doi: 10.1038/leu.2011.234. Epub 2011 Sep 2.
10
Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT.Wilms 瘤基因 1 表达：异基因造血干细胞移植后急性白血病的独立预后指标。
Bone Marrow Transplant. 2012 Apr;47(4):499-507. doi: 10.1038/bmt.2011.121. Epub 2011 Jun 6.